Reactions Weekly

, Volume 1746, Issue 1, pp 7–7 | Cite as

Anti-PD-1 antibodies followed by osimertinib: irAEs

Clinical study


  1. Schoenfeld AJ, et al. Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of Oncology : 7 Mar 2019. Available from: URL:

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations